Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.